SI-BONE, Inc.
SIBN Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2017βFY2025
What SI-BONE, Inc. does
No business description yet.
- Legal name
- SI-BONE, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 24, 2026
- Accession Β· CIK
- 0001459839-26-000036
0001459839
Revenue and margins
SI-BONE, Inc. had $201M of revenue in fiscal 2025, up 20.2% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$9.1M in fiscal 2025, β4.5% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
SI-BONE, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 3.6%.
Balance sheet
Cash, debt and the ratios that show how comfortably SI-BONE, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $147M | $97.3M | $33.3M | $34.9M | $42.2M |
| Debt incl. finance leases | $35.0M | $35.2M | $36.1M | $35.5M | $35.6M |
| Debt / equity | 0.3x | 0.4x | 0.2x | 0.2x | 0.2x |
| Interest coverage | β9.6x | β21.1x | β13.6x | β10.2x | β8.5x |
| Current ratio | 10.4x | 6.5x | 9.0x | 7.7x | 8.5x |
| Quick ratio | 9.7x | 5.7x | 8.1x | 6.7x | 7.2x |
| Total assets | $191M | $158M | $230M | $230M | $239M |
| Total liabilities | $56.1M | $59.3M | $61.1M | $63.5M | $61.0M |
| Shareholders' equity | $134M | $98.3M | $169M | $167M | $178M |
| Net debt (β = net cash) | β$112M | β$62.1M | $2.8M | $0.5M | β$6.7M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 9 | 2 / 9 | 4 / 9 | 3 / 9 | 2 / 9 | 4 / 9 | 5 / 9 | 6 / 9 |
| Accruals ratio | β15.4% | β3.4% | β5.3% | β7.7% | β8.2% | β11.3% | β12.7% | β8.0% | β7.8% |
| Altman Z'' | β14.10 | 3.70 | β1.10 | 4.67 | 1.11 | β3.34 | 1.23 | 0.77 | 1.52 |
9 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | $48.0M | $55.4M | $67.3M | $73.4M | $90.2M | $106M | $139M | $167M | $201M |
| Gross profit | $42.9M | $50.5M | $60.5M | $64.5M | $79.7M | $90.7M | $109M | $132M | $160M |
| Research and development | $5.5M | $5.4M | $7.3M | $9.5M | $12.4M | $13.6M | $15.0M | $16.6M | $17.4M |
| Operating income | β$17.4M | β$12.0M | β$36.0M | β$38.6M | β$51.7M | β$59.6M | β$46.9M | β$35.2M | β$22.3M |
| Interest expense | $6.2M | $5.1M | $4.9M | $6.1M | $5.4M | $2.8M | $3.5M | $3.4M | $2.6M |
| Pretax income | β$23.0M | β$17.5M | β$38.4M | β$43.7M | β$57.0M | β$61.4M | β$43.5M | β$31.1M | β$19.1M |
| Income tax | $0.0M | $0.0M | β | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$23.0M | β$17.5M | β$38.4M | β$43.7M | β$56.6M | β$61.3M | β$43.3M | β$30.9M | β$18.9M |
| Diluted EPS | β$6.65 | β$2.20 | β$1.55 | β$1.50 | β$1.71 | β$1.79 | β$1.13 | β$0.75 | β$0.44 |
| Diluted shares | 0.00B | 0.01B | 0.02B | 0.03B | 0.03B | 0.03B | 0.04B | 0.04B | 0.04B |
| Cash flow | |||||||||
| Cash from operations | β$17.5M | β$14.5M | β$31.6M | β$30.7M | β$39.5M | β$41.7M | β$18.7M | β$12.4M | β$0.7M |
| Capital expenditure | $0.5M | $0.9M | $2.4M | $2.6M | $6.4M | $9.5M | $7.8M | $10.5M | $8.4M |
| Free cash flow | β$18.0M | β$15.5M | β$34.1M | β$33.2M | β$45.9M | β$51.2M | β$26.5M | β$22.9M | β$9.1M |
| Depreciation and amortization | $1.0M | $0.7M | $0.8M | $1.1M | $2.1M | $3.5M | $5.4M | $4.4M | $5.8M |
| Stock-based compensation | $1.4M | $2.3M | $7.5M | $11.9M | $16.9M | $23.1M | $24.1M | $25.9M | $25.5M |
| Share buybacks | $0.0M | $0.1M | $0.0M | β | β | β | β | β | β |
| Dividends and buybacks | $0.0M | $0.1M | $0.0M | β | β | β | β | β | β |
| Balance sheet | |||||||||
| Cash and short-term investments | $22.4M | $122M | $91.8M | $196M | $147M | $97.3M | $33.3M | $34.9M | $42.2M |
| Total debt | $38.7M | $39.0M | $39.2M | $39.5M | $35.0M | $35.2M | $36.1M | $35.5M | $35.6M |
| Current assets | $33.6M | $136M | $111M | $218M | $176M | $138M | $211M | $208M | $216M |
| Current liabilities | $7.5M | $9.0M | $18.8M | $13.5M | $16.9M | $21.2M | $23.5M | $27.1M | $25.3M |
| Inventory | $2.6M | $3.3M | $5.5M | $5.6M | $11.5M | $17.3M | $20.2M | $27.1M | $33.9M |
| Property and equipment, net | $1.9M | $2.2M | $4.0M | $4.5M | $9.0M | $15.6M | $16.0M | $20.4M | $21.3M |
| Total assets | $35.8M | $139M | $117M | $223M | $191M | $158M | $230M | $230M | $239M |
| Total liabilities | $46.7M | $48.3M | $54.0M | $53.8M | $56.1M | $59.3M | $61.1M | $63.5M | $61.0M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$129M | $90.2M | $63.0M | $169M | $134M | $98.3M | $169M | $167M | $178M |
| Margins | |||||||||
| Gross margin | 89.3% | 91.3% | 89.9% | 87.9% | 88.4% | 85.2% | 78.8% | 79.0% | 79.6% |
| Operating margin | β36.2% | β21.6% | β53.5% | β52.6% | β57.3% | β56.0% | β33.8% | β21.1% | β11.1% |
| EBITDA margin | β34.0% | β20.3% | β52.3% | β51.0% | β55.0% | β52.8% | β29.9% | β18.5% | β8.2% |
| Net margin | β48.0% | β31.5% | β57.1% | β59.5% | β62.8% | β57.6% | β31.2% | β18.5% | β9.4% |
| FCF margin | β37.5% | β27.9% | β50.6% | β45.3% | β50.9% | β48.1% | β19.1% | β13.7% | β4.5% |
| Returns | |||||||||
| Return on capital | β | β136.4% | β272.1% | β246.0% | β182.1% | β130.1% | β21.5% | β16.6% | β10.3% |
| Return on capital employed | β61.3% | β9.2% | β36.6% | β18.4% | β29.8% | β43.7% | β22.7% | β17.3% | β10.5% |
| Return on equity | β | β | β50.1% | β37.6% | β37.2% | β52.6% | β32.4% | β18.4% | β11.0% |
| Return on assets | β64.3% | β20.0% | β30.1% | β25.7% | β27.4% | β35.2% | β22.3% | β13.4% | β8.1% |
| Return on tangible equity | β | β19.4% | β60.9% | β25.8% | β42.1% | β62.3% | β25.6% | β18.5% | β10.6% |
| Growth | |||||||||
| Revenue growth | β | 15.4% | 21.5% | 9.0% | 22.8% | 18.0% | 30.5% | 20.4% | 20.2% |
| Share count change | β | 129.3% | 210.8% | 17.6% | 14.1% | 3.2% | 12.4% | 7.9% | 3.6% |
| Financial health | |||||||||
| Debt / equity | β | 0.4x | 0.6x | 0.2x | 0.3x | 0.4x | 0.2x | 0.2x | 0.2x |
| Interest coverage | β2.8x | β2.3x | β7.3x | β6.3x | β9.6x | β21.1x | β13.6x | β10.2x | β8.5x |
| Current ratio | 4.5x | 15.1x | 5.9x | 16.2x | 10.4x | 6.5x | 9.0x | 7.7x | 8.5x |
| Quick ratio | 4.1x | 14.7x | 5.6x | 15.8x | 9.7x | 5.7x | 8.1x | 6.7x | 7.2x |
| Capital allocation | |||||||||
| Capex / revenue | 1.0% | 1.7% | 3.6% | 3.5% | 7.1% | 8.9% | 5.6% | 6.3% | 4.2% |
| Stock comp / revenue | 3.0% | 4.2% | 11.1% | 16.3% | 18.7% | 21.7% | 17.3% | 15.5% | 12.7% |
| Quality scores | |||||||||
| Piotroski F-score | β | 5.0 | 2.0 | 4.0 | 3.0 | 2.0 | 4.0 | 5.0 | 6.0 |
| Altman Z'' | β14.1 | 3.7 | β1.1 | 4.7 | 1.1 | β3.3 | 1.2 | 0.8 | 1.5 |
| Accruals ratio | β15.4% | β3.4% | β5.3% | β7.7% | β8.2% | β11.3% | β12.7% | β8.0% | β7.8% |
Source: SEC EDGAR XBRL filings (CIK 0001459839). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.